TY - JOUR
T1 - Notch reporter activity in breast cancer cell lines identifies a subset of cells with stem cell activity
AU - D'Angelo, Rosemarie C.
AU - Ouzounova, Maria
AU - Davis, April
AU - Choi, Daejin
AU - Tchuenkam, Stevie M.
AU - Kim, Gwangil
AU - Luther, Tahra
AU - Quraishi, Ahmed A.
AU - Senbabaoglu, Yasin
AU - Conley, Sarah J.
AU - Clouthier, Shawn G.
AU - Hassan, Khaled A.
AU - Wicha, Max S.
AU - Korkaya, Hasan
N1 - Funding Information:
This work was supported by the NIH grants CA101860 and CA129765, Susan G. Komen for the Cure Promise Award (KG120001), and a Breast Cancer Research Foundation Award (N015445)and research funding was provided by Merck & Co., Inc. (to M.S. Wicha). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Publisher Copyright:
© 2015 American Association for Cancer Research.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Developmental pathways such as Notch play a pivotal role in tissue-specific stem cell self-renewal as well as in tumor development. However, the role of Notch signaling in breast cancer stem cells (CSC) remains to be determined. We utilized a lentiviral Notch reporter system to identify a subset of cells with a higher Notch activity (Notch+) or reduced activity (Notch-) in multiple breast cancer cell lines. Using in vitro and mouse xenotransplantation assays, we investigated the role of the Notch pathway in breast CSC regulation. Breast cancer cells with increased Notch activity displayed increased sphere formation as well as expression of breast CSC markers. Interestingly Notch+ cells displayed higher Notch4 expression in both basal and luminal breast cancer cell lines. Moreover, Notch+ cells demonstrated tumor initiation capacity at serial dilutions in mouse xenografts, whereas Notch- cells failed to generate tumors. γ-Secretase inhibitor (GSI), a Notch blocker but not a chemotherapeutic agent, effectively targets these Notch+ cells in vitro and in mouse xenografts. Furthermore, elevatedNotch4 and Hey1 expression in primary patient samples correlated withpoor patient survival. Ourstudy revealed a molecularmechanismfor the role of Notch-mediated regulation of breast CSCs and provided a compelling rationale for CSC-targeted therapeutics.
AB - Developmental pathways such as Notch play a pivotal role in tissue-specific stem cell self-renewal as well as in tumor development. However, the role of Notch signaling in breast cancer stem cells (CSC) remains to be determined. We utilized a lentiviral Notch reporter system to identify a subset of cells with a higher Notch activity (Notch+) or reduced activity (Notch-) in multiple breast cancer cell lines. Using in vitro and mouse xenotransplantation assays, we investigated the role of the Notch pathway in breast CSC regulation. Breast cancer cells with increased Notch activity displayed increased sphere formation as well as expression of breast CSC markers. Interestingly Notch+ cells displayed higher Notch4 expression in both basal and luminal breast cancer cell lines. Moreover, Notch+ cells demonstrated tumor initiation capacity at serial dilutions in mouse xenografts, whereas Notch- cells failed to generate tumors. γ-Secretase inhibitor (GSI), a Notch blocker but not a chemotherapeutic agent, effectively targets these Notch+ cells in vitro and in mouse xenografts. Furthermore, elevatedNotch4 and Hey1 expression in primary patient samples correlated withpoor patient survival. Ourstudy revealed a molecularmechanismfor the role of Notch-mediated regulation of breast CSCs and provided a compelling rationale for CSC-targeted therapeutics.
UR - http://www.scopus.com/inward/record.url?scp=84931410524&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931410524&partnerID=8YFLogxK
U2 - 10.1158/1535-7163.MCT-14-0228
DO - 10.1158/1535-7163.MCT-14-0228
M3 - Article
C2 - 25673823
AN - SCOPUS:84931410524
SN - 1535-7163
VL - 14
SP - 779
EP - 787
JO - Molecular Cancer Therapeutics
JF - Molecular Cancer Therapeutics
IS - 3
ER -